High presence of extended-spectrum β-lactamases and resistance to quinolones in clinical isolates of Escherichia coli
Metadatos
Mostrar el registro completo del ítemAutor
Sorlozano Puerto, Antonio; Gutiérrez Fernández, José; Luna Del Castillo, Juan De Dios; Oteo, Jesús; Liébana Ureña, José; Soto, María José; Piédrola Angulo, GonzaloEditorial
Elsevier
Materia
Escherichia coli CTX-M9 Quinolones PFGE
Fecha
2007-03Referencia bibliográfica
Sorlózano A, Gutiérrez J, de Dios Luna J, Oteo J, Liébana J, Soto MJ, Piédrola G. High presence of extended-spectrum beta-lactamases and resistance to quinolones in clinical isolates of Escherichia coli. Microbiol Res. 2007;162(4):347-54. doi: 10.1016/j.micres.2006.02.003
Resumen
A study was conducted to detect the presence of extended-spectrum beta-lactamases (ESBLs) in 706 isolates of Escherichia coli, largely from outpatients (75.2%). The Clinical and Laboratory Standards Institute (formerly NCCLS)-recommended disk diffusion procedure was used to detect ESBL presence; the VITEK 2 system (bioMérieux, Marcy L'Etoile, France) was used to determine the susceptibility to antibiotics of clinical interest, and the ESBLs were characterized by biochemical study, determining the isoelectric point, and by molecular study with PCR. Clonal distribution was studied in eight hospital isolates. There were 115 ESBL-producing isolates (16.3%), with a predominance of CTX-M9 type (58.3%). We draw attention to the high resistance to quinolones (>70%) in CTX-M9 and SHV enzyme producing isolates and the lower aminoglycoside activity in the latter.